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Abstract
Prostate-derived Ets transcription factor (PDEF) has re-
cently been associated with invasive breast cancer, but
no expression profile has been defined in clinical spec-
imens. We undertook a comprehensive PDEF transcrip-
tional expression study of 86 breast cancer clinical
specimens, several cell lines, and normal tissues. PDEF
expression profile was analyzed according to standard
clinicopathologic parameters and compared with hor-
monal receptor and HER-2/neu status and to the ex-
pression of the new tumor biomarker Dikkopf-1 (DKK1).
Wide ranging PDEF overexpression was observed in
74% of tested tumors, at higher levels than the average
expression found in normal breasts. High PDEF expres-
sion was associated with hormone receptor positivity
(P < .001), moderate to good differentiation (less than
grade III, P = .01), and dissemination to axillary lymph
nodes (P = .002). PDEF was an independent risk factor
for nodal involvement (multivariate analysis, odds ratio
1.250, P = .002). It was expressed in a different sub-
group compared to DKK1-expressing tumors (P < .001).
Our data imply that PDEF mRNA expression could be
useful in breast cancer molecular staging. Further in-
sights into PDEF functions at the protein level, and
possible links with hormone receptors biology, bear
great potential for new therapeutic avenues.
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Introduction
Genome-wide expression profiles have provided a genotypic
ground that supports the main invasive breast cancer phe-
notypes, namely, the estrogen receptor (ER)-positive lu-
minal epithelial type, the ER-negative basal epithelial type,
and breast carcinoma overexpressing the HER-2/neu recep-
tor [1]. ER-positive tumors form the largest group of breast
cancers, but encompass heterogeneous tumors of variable
aggressiveness [2–4]. ER-positive tumor-specific genes,
which promote or prevent early dissemination or resistance to
antiestrogenic therapies, remain to be identified, included as
molecular staging tools, and used as new therapeutic targets to
personalize breast cancer treatment and improve outcomes.
Epithelial-specific Ets transcription factors could poten-
tially be exploited in this regard [5,6]. Several Ets have been
linked mainly to ER-negativity and HER-2/neu breast cancer
[7–10]. Prostate-derived Ets transcription factor (PDEF), one
of the last Ets identified, was the first to be characterized in
hormone-sensitive prostate cancer as a promoter of the pro-
tease prostate-specific antigen, in cooperation with androgen
receptor and other transcription factors [11,12]. Bioinformatic
tools and various gene expression quantification methods
subsequently documented PDEF mRNA overexpression in
invasive breast cancer [13], in atypical ductal hyperplasias,
and in carcinomas in situ [14], when compared to normal
breasts. PDEF mRNA has also been detected in micrometa-
static axillary lymph nodes [15]. Despite high mRNA expres-
sion, immunohistochemical data suggest that PDEF protein
expression could be lost in prostate and breast carcinomas
[16,17]. PDEF silencing and overexpression assays in breast
and prostate metastatic cancer cell lines resulted in antimeta-
static effects [18–20], but prometastatic effects has also been
documented in other metastatic- and benign disease–derived
breast cell lines [14].
Up to now, however, the PDEF expression profile has not
been described, at the mRNA level, in clinical breast cancer
specimens. In order to orient future work at the protein level,
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we report a comprehensive PDEF transcriptional expression
study of 86 breast cancer clinical specimens, several cell
lines, and normal tissues. PDEF expression profile was
analyzed according to standard clinicopathologic parame-
ters, compared with hormonal receptor and HER-2/neu
status, and to the expression of the new tumor biomarker
Dikkopf-1 (DKK1). We observed that PDEF expression is
strongly associated with the ER-positive breast cancer phe-
notype and that PDEF mRNA overexpression in primary
tumors could also be an independent risk factor for cancer
dissemination to lymph nodes.
Materials and Methods
Patient Specimens and Cell Lines
Breast cancer tissues of consecutive patients who had
provided written consent to contribute to the CHUM-FRSQ
Tumor Bank (Montreal, QC, Canada) between September
2003 and February 2006 were selected by the pathologist
after surgical resection of tumors 1.5 cm or greater in
diameter. The recruitment protocol and management of
clinical specimens and information were previously approved
by institutional authorities. Fresh tissues were stored at 4jC
in RNAlater (Sigma, St. Louis, MO) for RNA stabilization. All
patients underwent sentinel node dissection and, when
positive for nodal metastasis, complete axillary lymph node
dissection. Cell lines used for the first detection of PDEF at
the mRNA and protein levels (breast cancer MCF7, MDA-
MB-231, BT-20, HCC-1428, HCC-2218, renal embryonic
293T, and melanoma SK23) were obtained from the Amer-
ican Type Culture Collection (Manassas, VA) and cultured in
RPMI 1640 (Wisent, St.-Bruno, QC, Canada) supplemented
with 10% heat-inactivated FBS, 100 U/ml penicillin/strepto-
mycin (both from Wisent), 2 mM L-glutamine, and 10 mg/ml
gentamicin (both from Invitrogen, Grand Island, NY). HCC
breast cancer lines also required 10 mM Hepes solution plus
1 mM sodium pyruvate (both from Invitrogen). Mononuclear
cells were obtained by patient blood centrifugation on a
lymphocyte separation medium (Cellgro, Herndon, VA) and
culture in complete AIM-V medium (Invitrogen), as described
previously [21].
RNA Extraction and Reverse Transcription–Polymerase
Chain Reaction (RT-PCR)
Cancer specimens were homogenized with Medimachine
(Dako Cytomation, Glostrup, Denmark) according to the
manufacturer’s instructions. Total RNA was extracted with
a reagent (Qiazol; QIAGEN GmbH, Hilden, Germany), fol-
lowed by a cleanup and concentration procedure, using the
RNeasy Mini or Micro Kit (QIAGEN) and stored at 80jC.
Five of 91 clinical specimens were rejected because of poor
quality of the extracted mRNA (OD260/OD280 absorption ratio
below 1.6) or a b-actin expression level detected beyond the
last dilution of the standard curve when tested in real-time
PCR (see below). A panel of pooled mRNA from 19 normal
tissues and 6 peritumoral normal breast mRNA were also
analyzed (both from Clontech, Mountain View, CA).
We synthesized cDNA from 1 mg of mRNA with the Omni-
script Reverse Transcriptase (RT) Kit (QIAGEN), using oligo-
dT (Invitrogen) at 42jC for 1 hour. Intron-spanning PCR
primer pairs were designed for PDEF (5V primer GACATCGA-
GACGGCCTGCAAGCTG; 3V primer ACATGGCGCACA-
GCTCCTTG; amplicon 150 bp) and for b-actin, exploited as
a housekeeping gene (5V primer GGAAGGCTGGAAGA-
GTGCC; 3V primer GTGATGGTGGGC ATGGGT C; amplicon
300 bp) (Invitrogen). PCR was performed with the Quantitect
SYBR Green PCR kit (QIAGEN). Optimal annealing tem-
peratures for both PDEF and b-actin were determined by a
gradient (51–65jC). Real-time quantitative RT-PCR was per-
formed with 0.4 mM of each PDEF primer or 0.8 mM of each
b-actin primer, 6.25 ml of 2 SYBR Green mix (providing
2.5 mM MgCl2), 2.5 ml of cDNA (1:25 dilution), and water in
a thermal cycler (Rotorgene 3000; Corbett Life Science,
Sydney, Australia). The optimized cycling conditions were
10 minutes at 95jC for the initial polymerase activation, then
32 cycles for 40 seconds at 94jC, 40 seconds at 56jC,
50 seconds at 72jC, and a final melting curve from 72 to
95jC. Fluorescence was measured at the end of each ex-
tension step. The gain was adjusted automatically on the first
tube at the end of the first cycle (channel FAM/SYBR, source
470 nm, detector 510 nm, gain adjusted between 2 and
5 fluorescence). The absence of primer dimers and the
specificity of the PCR products were documented by melting
curve analysis and electrophoresis migration in 2% agarose
gel stained with ethidium bromide.
PDEF Quantification
The relative PDEF expression ratio over b-actin was
reported in relation to MCF7 cell line expression established
at a value of 1 [22]. The equation takes into account the PCR
efficiencies (E ) of both genes and the difference (D) between
the moment at which the fluorescence of a given sample
versus MCF7 crosses the threshold (Ct). The equation is
as follows:
Ratio PDEF=  actin ¼ EPDEFð ÞDCtðMCF7sampleÞ for PDEF


EactinÞDCtðMCF7sampleÞ for actin
Standard curves were generated every two runs with
serial dilutions of a pool of cDNA taken from the above-
mentioned breast cancer cell lines. The curves allowed the
software from Corbett to calculate the lowest thresholds of
the log-linear amplification phase above the fluorescence
background and the efficiencies of PCRs derived from the
high linearity slopes (Pearson correlation coefficient r >
0.99). Mean thresholds and efficiencies were used to com-
pare the expression of all samples. Ct obtained at or after the
last detectable point of the dilution curves (1:3125 for PDEF
and 1:15,625 for b-actin) was considered negative. All sam-
ples were tested in duplicate in at least two independent
runs, whereas MCF7 and the controls (MCF7 without RT,
water, or lymphocytes) were systematically included in every
run. Intra- and interassay Ct variations, calculated with the
Relative Expression Software Tool, are represented by error
bars [23].
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DKK1 Expression Measurements and Quantification
Real-timeRT-PCRwith intron-spanning DKK1 primerswas
performed in a thermal cycler (LightCycler; Roche, Mann-
heim, Germany) and revealed with SYBR Green (QIAGEN)
as described previously [24]. cDNA was synthesized as
described for PDEF, from the same RNA extracts, tested
at the same time period, and the amplified material was sub-
mitted to the same specificity validation as PDEF.
Measurement of PDEF Protein Expression
For Western blot analysis, protein extracts were prepared
from the above-mentioned cell lines for 20 minutes in lysis
buffer (20 mM Tris–HCl, pH 8, 137 mM NaCl, 10% glycerol,
1% Triton X-100, 1 mMNa3VO4, and 2 mMEDTA) containing
protease inhibitors (1 mM PMSF, 2 mM pepstatin A, and 2 mM
leupeptin, all from Sigma). Protein concentration was mea-
sured by Lowry’s assay with a DC Protein Assay kit (Bio-
Rad, Hercules, CA). For recombinant PDEF, the coding
sequence was cloned in pQE-30 (QIAGEN) and the re-
combinant protein was produced in Escherichia coli DH5-a.
Cell extracts (10 mg/well), resolved by 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, were trans-
ferred to polyvinylidene fluoride membranes (Immun-Blot,
Bio-Rad). The membranes were subjected to 1-hour incuba-
tion with rabbit affinity-purified polyclonal anti-PDEF antibody
(1:400), kindly provided by Dr. Dennis K. Watson (Hollings
Cancer Center, Charleston, SC) [16], or with mouse actin-
specific antibody (1:4000; Chemicon, Temecula, CA). The
membranes were then washed and proteins revealed after a
1-hour incubation with secondary peroxydase–conjugated
antibodies (1:5000 goat anti-rabbit from Santa Cruz Bio-
technology, Inc., Santa Cruz, CA; 1:40,000 goat anti-mouse
antibody from Chemicon) were detected with a reagent (ECL
Plus; Amersham Biosciences, Picastaway, NJ). Chemifluo-
rescence was quantified with an imaging system (Omega
12ic; Ultralum, Clarement, CA).
Statistical Analysis
Associations between PDEF continuous expression and
categorical clinicopathologic parameters were evaluated by
the independent-sample t test or by the one-way analysis of
variance (if more than two categories, with previous Levine
test to ensure the homogeneity of variance). PDEF versus
DKK1 proportions clustered by clinicopathologic factors were
compared by the Pearson chi-square test or Fisher’s exact
test for small samples. These tests were done using a soft-
ware for Windows (SPSS 13.0; LEAD Technologies, Chi-
cago, IL), with the generation of receiver–operator curves
(ROCs) to evaluate the sensitivity of PDEF expression for
the prediction of clinicopathologic factors. Univariate and
multivariate logistic regressions were used to compare the
strength of associations between PDEF continuous expres-
sion and metastatic lymph node involvement. Logistic re-
gression analysis was performed with software R, version
2.3.1, with the deviance test for multivariate analysis (The R
project for statistical computing [http://www.r-project.org]).
Figure 1. PDEF mRNA and protein expression in cancer cell lines. (A) Mi-
gration of PDEF amplicon obtained in cancer cell lines by real-time RT-PCR,
with relative quantification (PDEF/-actin, if MCF7 = 1.0). Four cell lines de-
rived from metastatic breast cancer (MCF7, BT-20, MDA-MB-231, and HCC-
1428) figure with SK23 melanoma, and 293T renal embryonic cells used as
negative controls. (B) PDEF expression at the protein level by Western blot
analysis. All results are representative of at least three independent experi-
ments. ER, estrogen receptor; PR, progesterone receptor; RT, without re-
verse transcription; rPDEF, recombinant PDEF; 293T + PDEF, 293T cells
transfected with PDEF.
Figure 2. PDEF expression in normal tissues. PDEF mRNA expression of
a panel of 19 mRNA pools of normal tissues. *‘‘Normal breast’’ corresponds to
the average level of six normal peritumoral breast tissues taken from patients
operated on for breast cancer. Controls (Ctl) include the MCF7 breast cancer
cell line and lymphocytes taken from the blood of breast cancer patients who
contributed to the CHUM-FRSQ Tumor Bank. The error bars represent the
intra- and interassay Ct variations, calculated with the Relative Expression
Software Tool, except for the normal breast, where it represents the standard
deviation of the six samples tested.
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All tests were two-sided and P values < .05 were regarded
as statistically significant.
Results
PDEF mRNA and Protein Expression in Breast
Cancer Cell Lines
PDEF expression at the mRNA and protein levels was
first evaluated in four breast cancer cell lines (Figure 1). The
ER-negative MDA-MB-231 breast cancer cell line expressed
the lowest PDEF level, five times lower than other ER-
positive lines. As reported previously, protein detection did
not always follow mRNA levels [16,17]. For further PDEF
mRNA expression analysis of clinical specimens, the MCF7
expression level was chosen as a reference because it
corresponded to the median PDEF/b-actin expression level
in breast cancer cell lines and is widely available.
PDEF mRNA is Weakly or Not Detected in Vital Organs
PDEF expression was previously reported by different
quantification methods in some high epithelial content tis-
sues, namely, the prostate, salivary glands, colon, and normal
breast [11,13,16]. We reassessed PDEF expression in normal
tissues to compare its magnitude with PDEF expression in
breast cancer by a reproducible method (Figure 2). Besides
weak expression in the lungs and colon, PDEF was not
detected in other vital organs, such as the heart, brain, and
Figure 3. PDEF expression in invasive breast carcinoma. (A) PDEF expression in 86 tested clinical samples. Sixty-four tumors were found to express PDEF at a
level at least equal to the MCF7 breast cancer cell line. (B) Higher PDEF expression was associated with moderate to well-differentiated (grades I and II) tumors,
with hormone receptor positivity (estrogen and/or progesterone), and with metastatic nodal involvement at the time of surgery. The same scale was used for the
three graphs. (C) Receiver –operator curves (ROCs) allowed the determination of the sensitivity and specificity at which the PDEF expression level was positively
associated with the three clinicopathological factors illustrated in (B). The MCF7 expression level (PDEF = 1) is indicated by arrows. AUC, area under the curve;
SE, standard error.
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kidneys. Mean PDEF expression in six peritumoral breast
tissues was 1.04 ± 0.68, a level similar to MCF7. PDEF was
absent from lymphocytes that often infiltrate solid tumors.
Altogether, the absence of PDEF expression in most normal
tissues and vital organs represents an essential prerequisite
for the validation of future tumor biomarker or antigen.
Measurement of PDEF in Breast Cancer Clinical Specimens
PDEF expression in breast cancer cell lines, which are
free of normal epithelium, combined with a similar level of
expression in peritumoral normal breasts, called for a com-
prehensive PDEF transcriptional analysis of breast cancer
clinical specimens. We were able to extract sufficient RNA
from 86 of 91 consecutive tumors. Mean patient age at
diagnosis was 64.5 years, and the majority presented with
moderately differentiated, sporadic, invasive ductal carcino-
mas. Among the 86 tumors, 64 (74.4%) were found to
express PDEF at a level at least equal to the established
MCF7 breast cancer cell line, and higher than the normal
breast average expression level (Figure 3A). PDEF expres-
sion ranged from 0 to 32 times higher than MCF7. Mean
PDEF expression in all tumors was 3.76 ± 4.46, with a
median of 2.80.
Cluster Analysis of PDEF By Clinicopathologic Parameters
Table 1 summarizes the clinicopathologic parameters of
patients and their tumors as well as the significance of the
different average PDEF expression cluster levels. Overall,
Table 1. PDEF Expression and Clinicopathological Factors of 86 Invasive Breast Cancers.
Clinicopathological Characteristics Frequencies* PDEF Expression and Association with Clinicopathological Factors
N (%) Mean 95% CI Py
Age
< 50 15 (17.6) 2.6 1.4–3.7
50 to 70 36 (42.4) 4.1 2.9–5.3
> 70 34 (40.0) 3.9 1.8–6.0 .516
Primary or relapse
Primary 68 (79.1) 3.2 2.5–3.9
Recurrence 10 (11.6) 7.5 0.2–14.8
Second primary, contralateral 8 (9.3) 4.0 1.7–6.2 .278
Familial history
No 60 (69.8) 4.4 3.1–5.7
Yes 26 (30.2) 2.4 1.4–3.4 .060
Histology
Ductal 66 (76.7) 3.4 2.6–4.3
Lobular 13 (15.1) 5.7 0.6–10.7
Other 7 (8.1) 3.6 0.6–6.7 .267
Histopathological gradez
I (good) 13 (15.1) 6.0 1.1–10.9
II (moderate) 41 (47.7) 4.6 3.5–5.8
III (poor) 31 (36.0) 1.7 0.9–2.5 .003**
Tumor size
T1 (V 2 cm) 33 (38.4) 3.6 1.7–5.6
T2 (2.1–5 cm) 46 (53.5) 4.1 3.0–5.2
T3 (> 5 cm) 7 (8.1) 2.3 0.1–4.6 .614
Metastatic axillary nodes§
Negative 40 (46.5) 2.4 1.6–3.2
Positive 37 (43.0) 4.3 3.4–5.3 .002
Combined staging (American Joint Committee on Cancer)
I 20 (23.3) 2.3 1.5–3.2
IIA 28 (32.6) 2.7 1.7–3.8
IIB 16 (18.6) 5.8 4.2–7.3 V .003yy
IIIA 8 (9.3) 3.1 0.7–5.5
IIIC 5 (5.8) 3.4 0.3–7.1
Estrogene receptor statusb
Negative 31 (36.0) 2.0 0.6–3.4
Positive 54 (62.8) 4.9 3.6–6.1 .003
Progesterone receptor statusb
Negative 37 (43.0) 2.0 1.1–2.9
Positive 48 (55.8) 5.2 3.8–6.7 .001
HER-2/neu overexpression#
Negative 73 (84.9) 4.0 2.9–5.2
Positive 5 (5.8) 2.9 0.5–6.3 .596
PDEF, prostate-derived Ets transcription factor; CI, confidence interval.
*Data do not always add up to 86 due to missing values.
yP value of Student’s t test for independent samples or one-way ANOVA when there was more than two categorical variables.
zScarff Bloom and Richardson classification, combined grade.
§Nodal status is dichotomized since only 11 tumors were associated with four or more nodes (N2 and N3).
bImmunohistochemical classification.
#Immunohistochemical classification (TAB 250 and CB11) confirmed by fluorescent in situ hybridization when doubtful.
**Average PDEF expression of grade III tumors is significantly lower than grade II or I.
yyAverage PDEF expression of stage IIB is higher than stage I or IIB tumors, but not significantly different from stage III tumors.
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these results provide an association between PDEF expres-
sion and sporadic epithelial ER-positive breast cancers that
are better differentiated (histopathological grades I and II)
than ER-negative tumors (Figure 3B). At the time of diag-
nosis, breast cancer can be regionally disseminated to the
axillary lymph nodes. PDEF overexpression in the primary
tumor was associated with these more advanced node-
positive tumors (Figure 3B). No association was found with
patient age, tumor size, ductal, or lobular histological type.
The limited number of recurrent tumors and tumors over-
expressing HER-2/neu did not yield statistical significance.
PDEF Expression is Strongly Associated with Hormone
Receptor Status
We observed that seven patients who presented an ER-
positive primary tumor and who had taken a 5-year course of
Table 2. Univariate and Multivariate Analyses of Metastatic Nodal Involvement in the Set of Clinical Samples Tested for PDEF Expression.
Clinicopathological Characteristics Univariate Multivariate*
P Odds Ratio (95% CI) P Odds Ratio (95% CI)
PDEF expression (continuous) .002 1.34 (1.10–1.62) .002 1.250 (1.004–1.540)
Differentiation, grade III vs I and II .08 0.41 (0.14–1.08) .42 0.51 (0.14–1.88)
Tumor size, > 2 cm vs V 2 cm .03 3.12 (1.12–8.70) .10 2.75 (0.89–8.34)
HER-2/neu, positive vs negative .93 1.09 (0.14–8.25) .48 2.38 (0.21–27.00)
CI, confidence interval.
*The multivariate model included 69 tumors, with 8 recurrent tumors for women who had already undergone axillary dissection for the primary tumor, 8 missing
values for HER-2/neu, and 1 missing tumor grade.
Figure 4. PDEF and DKK1 differential expression pattern. PDEF (upper charts) and DKK1 (lower charts) transcriptional expression are presented in three groups.
Group A comprises less differentiated, hormone receptor–negative tumors. DKK1 is overexpressed in Group B, with concomitant null or weak PDEF expression.
Group C corresponds to tumors in which PDEF is overexpressed. Compared with Groups A and B, Group C tumors more frequently involve axillary lymph nodes
(Nodes+), although better differentiated (less than grade III) and hormone receptor–positive. ER, estrogen receptor; MDA231, breast cancer cell line (experimental
control); PR, progesterone receptor; T cell, T lymphocytes.
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antiestrogen therapy (Tamoxifen) to prevent tumor recur-
rence nevertheless relapsed with ER-positive tumors coex-
pressing PDEF. The mean PDEF expression in these tumors
was 8.1, but the sample size was insufficient to reach
statistical significance (data not shown). Among all tumors
expressing PDEF, only 10 did not express ER, further
reinforcing a close link between ER and PDEF. We then
generated a ROC analysis to appreciate the sensitivity and
specificity at which PDEF expression could predict an asso-
ciation with hormone receptor positivity (Figure 3C). As
expected from the five times higher mean PDEF expression
in hormone receptor–positive tumors (Figure 3B), the ROC
analysis allowed us to predict hormone receptor positivity
with 98.3% sensitivity (58/59) and 76.9% specificity (20/26),
when PDEF was at or above the MCF7 level. These findings
all suggest a strong association between PDEF and the
hormone receptor–positive phenotype of breast cancer.
PDEF Overexpression is an Independent Risk Factor
for Cancer Dissemination to Axillary Lymph Nodes
The ROC generated for the prediction of nodal involve-
ment was less discriminatory than for hormone receptors
(Figure 3C). We, however, compared the strength of this
association to standard pathological characteristics, be-
cause regional dissemination of cancer to lymph nodes is
the strongest predictor of recurrence and death from breast
cancer. Univariate analysis revealed that PDEF expression
was a better predictor of nodal involvement than the degree
of differentiation, tumor size and HER-2/neu status (Table 2).
Continuous PDEF expression remained the only signifi-
cant independent risk factor in multivariate logistic regres-
sion analysis. In this model, sensitivity and specificity were
87.8% (29/33) and 38.8% (14/36), respectively. The asso-
ciated positive predictive value was 56.9% (29/51), and the
negative predictive value, 77.8% (14/18). The odds of pres-
enting nodal metastasis at the time of surgical management
were hence increased by 25% for each one-point elevation
of PDEF expression (odds ratio 1.250, 95% confidence in-
terval 1.004–1.540, P = .002). PDEF expression in the pri-
mary tumor thus appeared to be of interest as a molecular
staging tool.
PDEF and DKK1 Expressions Delineated Different
Subgroups of Aggressive Breast Cancers
The secreted protein DKK1, involved in the Wnt/b-catenin
canonic pathway, is emerging as a biomarker of shorter
cancer survival [25]. We recently reported that DKK1 was
preferentially expressed, at the transcriptional level, in the
aggressive subgroup of ER-negative invasive breast can-
cers [24]. Since it was recently documented that PDEF could
modulate the Wnt/b-catenin pathway [19], we wanted to
compare the PDEF and DKK1 expression profiles. PDEF
expression was effectively lower in DKK1-expressing tumors
(1.7 ± 1.4 vs 5.9 ± 3.2, P < .001) (Figure 4), and DKK1 was
not detected among high PDEF-expressing tumors. It was
confirmed that PDEF was expressed in a different subgroup
of tumors than DKK1. PDEF-expressing tumors were better
differentiated (lower than grade III, P = .01); a higher pro-
portion expressed ER (93% vs 43%, P = .001) and were
disseminated to axillary lymph nodes (66% vs 38%, P =
.01). In summary, PDEF and DKK1 could delineate distinct
aggressive subgroups of invasive breast cancers. The prog-
nostic significance of DKK1 and PDEF in terms of disease-
free survival and overall survival remains to be evaluated.
Discussion
This is the first study to assess the expression profile of
PDEF, measured as a continuous variable, by a highly
reproducible quantification method, in a substantial number
of clinical specimens, characterized for classic clinicopatho-
logic parameters. The first main finding was the strong
association between PDEF and the hormone receptor–
positive breast cancer phenotype. The second was that high
PDEF mRNA expression in the primary tumor was associ-
ated with a higher risk of regional metastasis to the lymph
nodes, which remains the most important prognostic factor
for survival at the time of breast cancer diagnosis.
High PDEF mRNA expression needs to be interpreted in
relation to low PDEF protein expression found in prostate
and breast carcinomas, when compared to normal tissues
[16,17,20]. Specifically for breast cancer, immunohistochem-
ical nuclear staining of PDEF was shown to be higher in the
peritumoral normal breast epithelium compared to carci-
noma cells of all differentiation grades, among 7 and 14 clinical
samples [16,20]. These authors noted the near absence of
PDEF in the less differentiated grade III tumors. PDEF
protein expression was unfortunately not compared with
respective mRNA expression or ER status in the clinical
samples tested, which limits comparison with our study.
Several observations can, however, be made. We have
described significantly low PDEF mRNA expression in
grade III tumors when compared to grades I and II (Fig-
ure 3B), which appears consistent with a PDEF downregu-
lation and low protein detection in grade III tumors. This is
reconcilable with a scheme of epithelial to mesenchymal
transition to neoplasia, in which PDEF expression could be
lost during cancer progression. However, we cannot exclude
that the majority of the few clinical specimens stained for
PDEF was ER-negative in the studies cited. Low PDEF
protein detection could also reflect the expected low PDEF
transcription level in this ER-negative tumor phenotype, as
we have observed at the mRNA level.
Nevertheless, low PDEF mRNA expression in normal
breasts still translates into high protein nuclear detection
[16]. Furthermore, low PDEF mRNA expression in breast
cancer cell lines can be associated with sizeable protein
expression (see MDA-MB-231, Figure 1), and high PDEF
mRNA expression, with barely detectable protein (see HCC-
1428, Figure 1). If PDEF is not mutated in cancer cells, it sug-
gests the occurrence of posttranscriptional mechanisms, such
as protein cleavage, homo- or heterodimerization, as reported
for other Ets factors [6], fast degradation due to two sequences
rich in proline, glutamic acid, serine, and threonine motifs con-
tained in PDEF [11], or cytoplasmic instead of nuclear pooling
[20]. If PDEF would qualify as a therapeutic target, it would
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further be important to investigate its protein expression in low
PDEF mRNA normal tissues, such as the lungs and colon
(Figure 2).
The link between PDEF and cell motility has been the
subject of recent publications. In clinical samples, we ob-
served an increased risk of nodal metastasis when PDEF
was highly transcript in the primary tumor (Figure 3B and
Table 2). Other groups have documented PDEF mRNA
overexpression in breast cancer micro- and macrometas-
tasis to lymph nodes [15,26]. These data suggest that PDEF
can be transcribed in invasive breast cancer and that PDEF
could have a role in molecular staging, provided that an
impact on patient survival would be further demonstrated
prospectively and have an impact on clinical decision making.
Considering the heterogeneity of breast cancers presenting
lymph node metastasis, it is too speculative to think that the
altered expression of one gene alone could accurately predict
nodal involvement from a primary tumor sample. We believe
that the potential role of PDEF in molecular staging lies in
multigene predictive models [3,27].
The association between PDEF mRNA overexpression
and nodal metastatis has to be discussed in light of the
recent work done on cell migration. Most studies have
concluded that PDEF was antimetastatic [16,18–20]. In
short, PDEF overexpression in transfected cell lines derived
from approximately eight breast or prostate cancer metas-
tases resulted in decreased cell migration, loss of pseudopods,
spheroid–morphological changes, and increased proportion
of cells in the G0 phase of the cell cycle. Opposite effects
were observed in PDEF knockdown cells (small interfering
RNA). Some underlying genetic mechanisms were also
proposed to support the decrease in cell invasiveness,
conditioned by PDEF, namely, the reduced urokinase plas-
minogen activator and increased Maspin [16], Survivin
downregulation [20], and interaction with the transforming
growth factor-b pathway [19]. In contrast, PDEF overexpres-
sion yielded prometastatic effects in transfected normal
endothelial cells, in normal breast cells, in the MCF10A be-
nign breast fibrocystic disease, in four pleural metastasis–
derived breast cancer cell lines, in one melanoma, and in
one colon cancer cell line [14]. Interestingly, coexpression of
PDEF and activated receptor tyrosine kinase Her-2/neu, or
colony-stimulating factor receptor, synergistically enhanced
MCF10A metastatic attributes. How can the apparent bimodal,
anti-, and prometastatic effects of PDEF be explained?
Three aspects may be considered in this regard. First, the
loss of PDEF protein expression, combined with high PDEF
mRNA expression, could be a stronger marker of prometa-
static characteristics in advanced breast cancers. Secondly,
PDEF overexpression in lower-grade tumor, as well as in
normal breast, may participate in the initiation or progres-
sion of early breast cancer. In fact, most antimetastatic
results have been documented in MDA-MB-231 mesenchymal-
like, ER- and HER-2/neu–negative pleural metastasis
breast cancer cell lines [16,18], and in the PC-3 androgen–
independent prostate cancer bone metastasis cell line [19].
Conversely, convincing prometastatic effects were noted in
the benign breast disease MCF10A cell line [14]. Finally,
PDEF may function as a transcription activator or repressor,
contingent on the cellular context, particularly through coop-
eration with hormone receptors [11] and the extracellular-
regulated kinase/mitogen-activated protein kinase signaling
pathway.
In conclusion, the PDEF transcriptional expression profile
in clinical samples suggests potential uses in molecular
staging, possibly for the heterogeneous subgroup of ER-
positive tumors, and for early lymph node metastasis diag-
nostic purposes. Further findings on PDEF protein biology
are needed to conclude if PDEF could represent an appro-
priate therapeutic target.
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